Request callback

NHS Branded Medicines Framework for North of England and Midlands and East – 1 March 2024

NHS England

Publication date 26 February 2024, 12:50pm
Contract location
UK - United Kingdom
Awarded supplier(s) Celltrion Healthcare United Kingdom Limited, Biogen, Neon Healthcare Ltd, Pfizer Ltd, Bayer Plc, Sandoz Ltd, Aventis Pharma ltd t/a Sanofi, Mylan, Merck Serono Limited, Janssen-Cilag Ltd, Eli Lilly and Company Ltd, Roche Products Ltd, Ipsen, Napp Pharmaceuticals Ltd, CST Pharma Limited, Orifarm UK, Teva UK Limited, Novo Nordisk, Novartis Pharmaceuticals UK Ltd, Zentiva Pharma UK Ltd, GlaxoSmithKline UK Limited, Celltrion Healthcare United Kingdom Limited, Merck Sharpe and Dohme (UK) Limited, Accord-UK Ltd, Dr.Reddy's Laboratories (UK) Limited, Pfizer Ltd, Aventis Pharma ltd t/a Sanofi, Sun Pharma UK Ltd, Sobi (Swedish Orphan Biovitrum Ltd), Galapagos Biotech Ltd, Thornton and Ross Ltd, AstraZeneca, Janssen-Cilag Ltd, Eli Lilly and Company Ltd, Roche Products Ltd, Almirall, Orifarm UK, Teva UK Limited, Novartis Pharmaceuticals UK Ltd, Gedeon Richter UK Ltd, Amgen Ltd, Accord-UK Ltd, Pfizer Ltd, Sandoz Ltd, Vifor Pharma UK Ltd, Chugai Pharma UK Ltd, Abbvie Ltd, Merck Serono Limited, Janssen-Cilag Ltd, Roche Products Ltd, Ipsen, Merz, Napp Pharmaceuticals Ltd, Pharmacosmos UK Ltd, Zentiva Pharma UK Ltd, GlaxoSmithKline UK Limited, Celltrion Healthcare United Kingdom Limited, Merck Sharpe and Dohme (UK) Limited, Accord-UK Ltd, Dr.Reddy's Laboratories (UK) Limited, Pfizer Ltd, Aventis Pharma ltd t/a Sanofi, Sobi (Swedish Orphan Biovitrum Ltd), Galapagos Biotech Ltd, Thornton and Ross Ltd, AstraZeneca, Janssen-Cilag Ltd, Eli Lilly and Company Ltd, Roche Products Ltd, Organon Pharmaceuticals UK Ltd, Orifarm UK, Teva UK Limited, Novartis Pharmaceuticals UK Ltd, Gedeon Richter UK Ltd
Total value £74

Project Title: NHS Branded Medicines Framework for North of England and Midlands and East – 1 March 2024

Offer reference number: CM/PHR/22/5678

CM/PHR/22/5678/01 – NHS Framework for NORTH OF ENGLAND Branded Medicines – Tranche B. Period of framework: 1 March 2024 to 31 August 2025 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months.

CM/PHR/22/5678/02 – NHS Framework for NORTH OF ENGLAND Branded Medicines (to transition to Tranche B) Period of framework: 1 March 2024 to 31 August 2025 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months.

CM/PHR/22/5678/03 – NHS Framework for MIDLANDS AND EAST of England Branded Medicines – Tranche A. Period of framework: 1 March 2024 to 31 August 2026 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 12 months

CM/PHR/22/5678/04 – NHS Framework for MIDLANDS AND EAST of England Branded Medicines (to transition to Tranche B). Period of framework: 1 March 2024 to 31 August 2025 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 12 months

NHS Branded Medicines Framework for North of England and Midlands and East – 1 March 2024